Member Info for sajy

This is what Justin Urquhart Stewart, city expert had to say about our new Chairman.

'He takes up roles at businesses where he can pick up significant shareholdings which will give him a windfall.

'His track record has been gaining the chairmanship of businesses where there's likely to be a corporate action – usually a sale – which means he'll be a swift beneficiary.

'Quite often you'll see he is the lightning rod for a corporate transaction to be carried out.'

You think Dest is punt? Find me another company that has 2 phase 3 ready drugs that have billion dollar markets, one licensed and major pharma showing an interest in the other with a Mcap of around £32M. If you can't see the opportunity here then ask yourself this, why would our new CEO be leaving an $8B company to join a £32M company?

I will apologise upfront for this post. I know many on here are suffering a big loss on their investment, as I am also. The aim of this post is to bring to your attention a company that I think will do very well and urge you to research it. The company is Destiny Pharma (Dest) and I have a substantial holding in it. I will give a few brief points about it.

1. It has 2 phase 3 ready drugs - one is licensed already and in discussions with partners for the other.

2. NIAID of USA is paying for pre clinical trials for one of the drugs XF-73 with a view for using it in wounds for the USA army.

3. Excellent results for Sporcov for Covid and influenza.

4. New CEO appointed - Was at GW Pharma that got taken over for $7.2B, currently at Jazz pharma $8.3B. Also worked for GSK. Why would he join a company that has a mcap of £29M.

5. I believe XF-73 will be standard of care for almost every operation in the future, try putting a price on that.

I won't bore you with anymore, but feel free to come to the Dest chat and ask any questions you may have. Once again apologies for this off topic post.

Justin sums it up nicely in the video below.

https://t.co/EK55zN44yc

Any idea what all those big trades are from Friday? Normally lucky to see a couple of trades.

Just going to put here what I am hearing, take it with a pinch of salt. The in vivo data is looking very good ( this was more or less confirmed in the recent presentation) and we are likely to sign 2 types of deals with interested parties. Now the interesting part is that we have partnerships with pharma companies that are likely to sign deals if the data is good enough, however a number of companies that do not have partnerships with us have also approached the company and want to see the data with a view to signing a deal. The deals will be either a technology platform partnership or we will license the platform.

The incoming CEO was part of GW Pharma that was taken over for $7.2B. He knows how to do great deals and will either sign a licensing deal for XF-73 or sell the rights to it. To buy the rights they will have to pay over $200M for them as a minimum, which is over £2 a share. Just shows how ridiculously cheap Dest is at present.

Taken a starter position here. Need to do more research before adding further. If anyone on here could assist with the following it will be much appreciated.

The warrants at $11.50, what do they equate to in pounds?

The FDA submission in 2023- when is that likely to happen and how long for FDA to respond?

Thanks

The following in the RNS caught my eye. '' I am really looking forward to September, when I can take over the reins from Debra, who has made a significant impact in a short space of time."

We know Debra was leading the discussions for XF-73, so could we have entered exclusive discussions with a potential partner, otherwise why mention significant impact. Just my thoughts.

First Debra and now Chris, both worked for GSK. This won't do any harm to the rumors that GSK is interested in XF-73. Will be interesting to see if the new chairman is in any linked to GSK.

That was the main reason I bought more at around 7p and averaged down. I do think that will be the last director buy for now as they will be in a closed period soon if not already.

It is obvious the data is looking very good, was hinted at in the presentation. A number of parties are waiting to see the data before committing to deals. As per the presentation Iain said the in vivo data will be available any day now. At this price it has to be a strong buy.

Looks like drilling at NC has started.

The reason the CEO was pushed was due to the poor deal for M3, only $1m upfront and a placing at a crappy price of 35p. The company received a lot of stick from shareholders for that deal and ultimately the CEO paid the price.

The reason for the drop is that most probably were expecting the discussions to be at a more advanced stage than they are. What most are missing is that some very big players in the pharma space are interested in XF-73 and the company wants one of the big boys as partner with some very large numbers in the licensing deal. They will not rush this deal and I am more than happy to wait for the right deal and partner. Would love for the partner to be GSK.

You missed the important bit in the RNS. In discussions with GLOBAL partners, from what I am hearing 2 Hugh pharma are interested in XF-73. The company won't be rushing this deal and expect this deal to blow away the licensing deal for M3.

For no reason, LOL. Did you not watch the IM presentation? Have you not seen the Director buys?

He will not get the £175K bonus as he had to spend £75K in purchasing shares before March 2023. He spent £55K and only needed to spend another £20K to claim the £175K bonus. So the question is why didn't he.

If the rumours are true this will rocket and is probably the reason for the high volume of late.

Decent volume again so far today. Antimicrobial resistance news in the telegraph might be helping, see below.

https://t.co/VBw13rIWRY